{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"082-398-404-952-09X","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"082-398-404-952-09X","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8901,"type":"PATENT","title":"University of Michigan Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":14369,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8216,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners= \"Univ Michigan\", \" Michigan Univ\", \" Univ Michigan NOT state NOT tech NOT Eastern\", \"Univ Michigan NOT technological\", \" Univ Michigan NOT Western\"
Select more for logical variants
Add to collection
Total patent : 14104
Search Applicants and Owners= \"Univ Michigan\", \" Michigan Univ\", \" Univ Michigan NOT state NOT tech NOT Eastern\", \"Univ Michigan NOT technological\", \" Univ Michigan NOT Western\"
Select more for logical variants
Add to collection
Total patent : 14104
wherein the chimeric polypeptide comprises a first domain comprising a bioluminescent or chemiluminescent polypeptide, or a heterologous kinase, and a second domain comprising at least one silencing moiety, and an endogenous protease cleavage motif positioned between the first and second domains\n
wherein the nucleic acid encodes a chimeric polypeptide comprising a first domain comprising a bioluminescent or chemiluminescent polypeptide, or a heterologous kinase, and a second domain comprising at least one silencing moiety, and an endogenous protease cleavage motif positioned between the first and second domains."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["The kit of claim 35, further comprising a substrate for the bioluminescent or chemiluminescent polypeptide or the heterologous kinase."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["The kit of claim 35, wherein the instructions are for measuring apoptosis in a living subject."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical formulation comprising a chimeric polypeptide and a pharmaceutically acceptable excipient suitable, \n
wherein the chimeric polypeptide comprises a first domain comprising a bioluminescent or chemiluminescent polypeptide, or a heterologous kinase, and a second domain comprising at least one silencing moiety, and an endogenous protease cleavage motif positioned between the first and second domains."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 38, further comprising a substrate for the bioluminescent or the chemiluminescent polypeptide or the heterologous kinase."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 39, wherein the chemiluminescent polypeptide is luciferase and the substrate is luciferin."],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 39, wherein the heterologous kinase is 8-[18F] fluoroganciclovir (FGCV) and the substrate is a herpes simplex virus-1 thymidine kinase (HSV-1 TK)."],"number":41,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition of claim 38, further comprising a liposome."],"number":42,"annotation":false,"claim":true,"title":false},{"lines":["A method for detecting a protease activity in a sample comprising \n
(a) contacting a polypeptide as set forth in claim 1 with a sample containing or suspected of containing a protease under conditions allowing cleavage of the endogenous protease cleavage motif, wherein the protease is capable of cleaving the endogenous protease cleavage motif; and\n
(b) detecting the amount of bioluminescent or a chemiluminescent signal in the sample, thereby detecting a protease activity in the sample."],"number":43,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 43, wherein the contacting is in solution, in solid phase or is in a cell in vitro, in situ, or in vivo."],"number":44,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 43, wherein the endogenous protease specifically cleaves the endogenous protease cleavage motif."],"number":45,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 45, wherein the endogenous cellular protease comprises a caspase."],"number":46,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 43, wherein the endogenous cellular protease comprises a caspase 3, a caspase 6, a caspase 7, a procaspase 8, a caspase 8, a caspase 9, a caspase 10, a matrix metalloproteinase (MMP) or a gamma-secretase."],"number":47,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 43, further comprising providing a substrate for the bioluminescent or chemiluminescent polypeptide, or the heterologous kinase, and administering the substrate before, with or after administration of the bioluminescent or chemiluminescent polypeptide or the heterologous kinase."],"number":48,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 48, wherein the chemiluminescent polypeptide is luciferase and the substrate is luciferin."],"number":49,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 48, wherein the heterologous kinase is 8-[18F] fluoroganciclovir (FGCV) and the substrate is a herpes simplex virus-1 thymidine kinase (HSV-1 TK)."],"number":50,"annotation":false,"claim":true,"title":false},{"lines":["A method for identifying the presence of a caspase in a sample comprising \n
(a) contacting a polypeptide with a sample under conditions allowing cleavage of the endogenous protease cleavage motif,\n
wherein the polypeptide comprises a chimeric polypeptide comprising a first domain comprising a bioluminescent or chemiluminescent polypeptide, or a heterologous kinase, and a second domain comprising at least one silencing moiety, and an endogenous protease cleavage motif positioned between the first and second domains, and, the endogenous protease cleavage motif is a cleavage motif specific for the caspase; and\n
(b) detecting the amount of bioluminescent or a chemiluminescent signal in the sample, thereby identifying the presence of the caspase."],"number":51,"annotation":false,"claim":true,"title":false},{"lines":["A method for detecting apoptosis in a cell comprising \n
(a) contacting a polypeptide with the cell under conditions allowing cleavage of the endogenous protease cleavage motif by a cellular enzyme,\n
wherein the polypeptide comprises a chimeric polypeptide comprising a first domain comprising a bioluminescent or chemiluminescent polypeptide, or a heterologous kinase, and a second domain comprising at least one silencing moiety, and an endogenous protease cleavage motif positioned between the first and second domains, and, the endogenous protease cleavage motif is a cleavage motif specific for an enzyme associated with apoptosis; and\n
(b) detecting the amount of bioluminescent or chemiluminescent signal in the cell, thereby identifying the presence and activity of the apoptosis-associated enzyme and detecting apoptosis."],"number":52,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 52, wherein the contacting is in a cell, a tissue, an organ or an entire body in vitro, in situ, or in vivo."],"number":53,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 53, wherein the cell, tissue or organ is undergoing aberrant proliferation or aberrant degeneration."],"number":54,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 53, wherein the aberrant proliferation comprises hyperproliferation."],"number":55,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 53, wherein the cell comprises a benign or a metastatic tumor."],"number":56,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 53, wherein the cell comprises a solid tumor."],"number":57,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 53, wherein the aberrant proliferation comprises deficient proliferation."],"number":58,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 53, wherein the aberrant degeneration comprises decreased cell death or increased cell death."],"number":59,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 53, wherein the amount of bioluminescent or chemiluminescent signal in the cell can be imaged by computer assisted tomography (CAT), magnetic resonance spectroscopy (MRS), magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), bioluminescence image (BLI) or equivalent."],"number":60,"annotation":false,"claim":true,"title":false},{"lines":["A method for detecting changes in apoptosis in a cell comprising: \n
a) contacting a polypeptide with the cell under conditions allowing cleavage of the endogenous protease cleavage motif by a cellular enzyme,\n
wherein the polypeptide comprises a chimeric polypeptide comprising a first domain comprising a bioluminescent or chemiluminescent polypeptide, or a heterologous kinase, and a second domain comprising at least one silencing moiety, and an endogenous protease cleavage motif positioned between the first and second domains, and, the endogenous protease cleavage motif is a cleavage motif specific for an enzyme associated with apoptosis; and\n
b) detecting any change in an amount of bioluminescent or chemiluminescent signal in the cell, thereby identifying the presence and activity of the apoptosis-associated enzyme and detecting a change in cell apoptosis."],"number":61,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 61, wherein the apoptosis-associated enzyme comprises a caspase."],"number":62,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 61, wherein the contacting is in a cell, a tissue, an organ or an entire body in vitro, in situ, or in vivo."],"number":63,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 63, wherein the tissue comprises breast, brain, head or neck, eye, nasopharynx, lung, liver, pancreas, kidney, esophagus, stomach, small or large intestine, bladder, rectum, prostate, testicle, ovary, uterus, bone, muscle, skin or blood."],"number":64,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 63, wherein the cell comprises a subject undergoing a therapy that increases or decreases cell proliferation or cell death."],"number":65,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 65, wherein the subject has or is at risk of having a cell proliferative disorder or a cell degenerative disorder."],"number":66,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 66, wherein the cell proliferative disorder comprises cell hyperplasia."],"number":67,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 67, wherein the cell hyperplasia comprises a cancer."],"number":68,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 68, wherein the cancer is a lymphoma, a myeloma or a leukemia."],"number":69,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 68, wherein the cancer is a solid tumor."],"number":70,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 68, wherein the cancer is a metastatic tumor."],"number":71,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 68, wherein the cancer comprises a sarcoma or fibrosarcoma."],"number":72,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 68, wherein the cancer is a glioma or neuroblastoma."],"number":73,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 66, wherein the cell degenerative disorder is produced by a stroke, a heart attack or a partial or complete arterial obstruction."],"number":74,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 66, wherein the cell degenerative disorder afflicts neural tissue, muscular tissue, cardiac tissue or bone marrow cells."],"number":75,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 66, wherein the cell degenerative disorder is dementia, Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, Machado-Joseph disease, spino-cerebellar ataxias, Kennedy's disease, muscular dystrophy, multiple sclerosis, beta-thalasemia, sickle cell anemia, aplastic anemia, ischemia/reperfusion injury, rheumatoid arthritis or graft versus host disease."],"number":76,"annotation":false,"claim":true,"title":false},{"lines":["A method for monitoring the effectiveness of a therapy that modulates cell proliferation or cell survival in a subject comprising: \n
a) contacting a cell, a tissue or an organ in the subject, before therapy, with a polypeptide, under conditions allowing cleavage of the polypeptide by an endogenous cell protease associated with cell proliferation or cell survival,\n
wherein the polypeptide comprises a chimeric polypeptide comprising a first domain comprising a bioluminescent or chemiluminescent polypeptide, or a heterologous kinase, and a second domain comprising at least one silencing moiety, and an endogenous protease cleavage motif positioned between the first and second domains, and, the endogenous protease cleavage motif is a cleavage motif specific for an enzyme associated with cell proliferation or cell survival;\n
b) detecting the amount of bioluminescent or chemiluminescent signal in the cell, tissue or organ, thereby identifying the presence and activity of the cell proliferation- or cell survival-associated enzyme;\n
c) administering a therapy to the subject; and\n
d) detecting any change in the amount of bioluminescent or chemiluminescent signal in the cell, tissue or organ after the therapy,\n
wherein a change in the amount of bioluminescent or chemiluminescent signal after the therapy indicates the amount of cell proliferation or cell survival, thereby indicating the effectiveness of the therapy."],"number":77,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, further comprising re-contacting the cell, tissue or organ with the polypeptide as set forth in claim 1 after administering the therapy to the subject."],"number":78,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein effectiveness of the therapy is indicated by an increase in the bioluminescent or chemiluminescent signal after the therapy."],"number":79,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein effectiveness of the therapy is indicated by a decrease in the bioluminescent or chemiluminescent signal after the therapy."],"number":80,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein the therapy inhibits cell proliferation."],"number":81,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein the therapy stimulates cell death."],"number":82,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein the therapy stimulates cell proliferation."],"number":83,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein the therapy inhibits cell death."],"number":84,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein the therapy comprises anti-cancer therapy."],"number":85,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein the therapy comprises chemotherapy or radiation therapy."],"number":86,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein the therapy comprises a treatment for a cell degenerative disorder."],"number":87,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 87, wherein the cell degenerative disorder afflicts neural tissue, muscle tissue, cardiac tissue or bone marrow cells."],"number":88,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein the therapy comprises a treatment for ischemia."],"number":89,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein the therapy comprises a treatment for stroke, a heart attack or a partial or complete arterial obstruction."],"number":90,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 77, wherein the therapy comprises a treatment for dementia, Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, Machado-Joseph disease, spino-cerebellar ataxias, Kennedy's disease, muscular dystrophy, multiple sclerosis, beta-thalasemia, sickle cell anemia, aplastic anemia, ischemia/reperfusion injury, rheumatoid arthritis and graft versus host disease."],"number":91,"annotation":false,"claim":true,"title":false},{"lines":["A computer-implemented method for monitoring relative effectiveness of a therapy that modulates cell proliferation or cell survival in a subject comprising: \n
(a) providing an imaging device in operable association with a computer, wherein the imaging device is a computer assisted tomography (CAT) device, a magnetic resonance spectroscopy (MRS) device, a magnetic resonance imaging (MRI) device, a positron emission tomography (PET) device, a single-photon emission computed tomography (SPECT) device, a bioluminescence imaging (BLI) device or equivalent;\n
(b) taking an image of a defined area of the subject before or during therapy in which the area has been contacted with a polypeptide to image the amount of bioluminescent or chemiluminescent signal, wherein the endogenous protease cleavage motif is an endogenous cleavage motif specific for an enzyme associated with cell proliferation or cell survival, and the polypeptide comprises a chimeric polypeptide comprising a first domain comprising a bioluminescent or chemiluminescent polypeptide, or a heterologous kinase, and a second domain comprising at least one silencing moiety, and an endogenous protease cleavage motif positioned between the first and second domains;\n
(c) outputting the image data to the computer;\n
(d) administering a therapy to the subject and again imaging the defined area;\n
(e) comparing the image data obtained in step (b) with the image data obtained in step (d) with the computer to generate a differential histogram; and\n
(f) analyzing the differential histogram to quantitate any change in bioluminescent or chemiluminescent signal after therapy,\n
wherein a change in the amount or activity of the bioluminescent or chemiluminescent signal after the therapy indicates a relative effectiveness of the therapy in modulating cell proliferation or cell survival."],"number":92,"annotation":false,"claim":true,"title":false},{"lines":["A method for identifying an agent that modulates an enzyme activity comprising: \n
(a) contacting a sample comprising the enzyme with a polypeptide in the presence and absence of a test agent, wherein the endogenous cleavage motif is an endogenous cleavage motif specific for the enzyme,\n
wherein the polypeptide comprises a chimeric polypeptide comprising a first domain comprising a bioluminescent or chemiluminescent polypeptide, or a heterologous kinase, and a second domain comprising at least one silencing moiety, and an endogenous protease cleavage motif positioned between the first and second domains, and;\n
(b) measuring the amount of bioluminescent or chemiluminescent signal in the sample after adding the polypeptide and in the presence and absence of the test agent,\n
wherein an increase or decrease in the amount or activity of the bioluminescent or chemiluminescent signal in the presence of the test agent identifies the test agent as a modulator of the enzyme's activity."],"number":93,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 93, wherein the contacting occurs in solution or in solid phase."],"number":94,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 93, wherein the contacting occurs in a cell."],"number":95,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 93, wherein the cell comprises a tissue, an organ or an entire body."],"number":96,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 95, wherein the cell comprises a non-human transgenic animal."],"number":97,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 95, wherein the non-human transgenic animal is a mouse or a rat."],"number":98,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}